A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Bezlotoxumab (Primary)
  • Indications Clostridium-difficile-infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms MODIFY III
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Mar 2018 Planned initiation date changed from 15 Mar 2018 to 26 Mar 2018.
    • 13 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 18 Jan 2018 Planned initiation date changed from 29 Jan 2018 to 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top